anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system that are responsible for direct and indirect cytolytic killing of virally-transformed and/or cancer cells. Harnessing NK cells in cancer immunotherapy therefore, provides a direct cytotoxic effect on cancer cells which further stimulates further downstream adaptive anti-tumor immune responses against the cancer. In order to effect a more targeted killing of these tumor cells, using a monoclonal antibody (mAb) to direct these NK cells to the target site is feasible, provided a specific tumor antigen can be identified. In nasopharyngeal Carcinoma (NPC) and head and neck squamous cell carcinoma (HNSCC) where epidermal growth factor receptor (EGFR) is ubiquitously expressed, combining NK cell therapy with cetuximab (a chimeric mouse/human anti-EGFR monoclonal antibody) to direct these NK cells against these EGFR tumor targets is possible. In this study, we seek to enhance the antitumor activity of cetuximab to treat EGFR-positive head and neck cancers by combing infusion of activated expanded autologous NK cells with cetuximab. Patients selected for this trial are those with refractory NPC and HNSCC where no feasible therapeutic options are available. This is a lead-in phase I followed by a phase II study. The phase I study will enroll 9 patients and will test the feasibility and safety of this combination strategy and determine the tolerated dose of NK cell infusion (1x1\^06/kg or 1x10\^7/kg NK cells) in adult EGFR positive NPC and HNSCC patients. For the first 3 patients, each new patient will only be enrolled at least 3 weeks after treatment of the preceding patient to allow sufficient time to monitor toxicities. Initial phase of treatment consists of 7 weeks of cetuximab monotherapy. At week 8, clinical evaluation will be done to determine patients who are suitable to continue this study with NK cell therapy, based on the severity of toxicities encountered. Eligible patients will undergo apheresis (Day -10) to harvest NK cells. The collected NK cells will be expanded and activated in the laboratory. During cycle 1, cetuximab will be given on day 1 with subcutaneous IL-2 (three times per week for 2 weeks); followed by expanded NK cells on day 2. The purpose of IL-2 is to sustain activity of these NK cells in-vivo. Cetuximab will be administered weekly for additional 2 weeks following the NK cell infusion during cycle 1. For cycle 2 and 3, cetuximab monotherapy will be administered every 21 days. Clinical evaluation will be performed upon completion of cycle 3. Patients with stable disease or with partial response will be allowed to continue with a second NK infusion dose as per cycle 1, followed by additional 2 more cycles of cetuximab monotherapy (every 21 days).

.
[Object] The present invention relates to an information processing apparatus and method, and a program capable of improving convenience in a case where a prescription or a medication notebook is made electronically available. 
     [Solving Means] An in-hospital device 32 sends information of a prescription to a data server 91 and records the information therein after a patient has been examined. In addition, the in-hospital device 32 sends a dispensing reservation request to the data server 91. The dispensing reservation request includes a pharmacy ID indicating a pharmacy for which a dispensing is requested and a prescription ID. The the data server 91 records dispensing reservation information containing the prescription ID and the pharmacy ID in response to the dispensing reservation request. An in-pharmacy device 62 acquires the dispensing reservation information by monitoring the data server 91 regularly and detects whether a dispensing request has been received. If the dispensing request has been received, the in-pharmacy device 62 acquires the information of the prescription from the data server 91. As a result, dispensing can be started in the pharmacy before the patient comes. The present invention is applicable to an information processing system.
The current standard of care at the University of Iowa is to receive a pectoralis nerve block (PEC I/II) prior to surgery for mastectomy and reconstruction cases. The investigators will compare whether patients will have better pain control if they were to receive (PEC I/II block) before surgery or after the mastectomy. Patients undergoing mastectomies at the University of Iowa Hospitals clinics receive general anesthesia and a regional block for pain control. The most commonly employed regional anesthetic technique is a PECS I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PECS I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PECS II). The investigators will randomize patients into two groups and blind the patient and the research assistant collecting the data. Group I will have the block performed after induction of general anesthesia and prior to surgical incision by the anesthesiologist. Group II will have the block administered by the surgeon after mastectomy is performed and before reconstruction. On the day of surgery, the investigators will have patients fill out forms to measure pain catastrophizing and depression and anxiety. The investigators would like to measure if there is any difference in postoperative pain scores (visual analogue scale)-immediately post surgery in post-anesthesia care unit (PACU), and then on the admission unit every 4 hours for the first twenty four hours or on discharge (whichever time-point occurs sooner) and will collect the average pain scale of the day on post-op day (POD) 2,3,5 and 7 via patient communication electronic message in RedCap. The investigators will also measure intraoperative and post-operative narcotic use (converted to morphine equivalents), post-operative nausea and vomiting, length of (PACU) stay. In addition the investigators will also collect pain scores and pain catastrophic scale on POD 14 after surgery at their clinic visits to the surgeon. Other data collected will include time taken to perform block, post-operative infection rate and post-operative flap necrosis rate.
PURPOSE:To obtain cosmetics or quasi-drugs using in an emulsified state in finely cutting capsule and compulsorily mixing at using time by floating capsule bases sealing-in oils and fats component in each capsule containing agar-agar and capsule-destroying agent in an aqueous solution component. CONSTITUTION:Agar-agar and a capsule-destroying agent (e.g. powdery pigment such as sericite or titanium oxide) are mixed in purified water to form a capsule. Then oils and fats-component is sealed in the resultant capsule to prepare a capsule base, thus the capsule is mixed into an aqueous solution component received in a vessel in a floating state and stored. As said vessel, a vessel having take-out mechanism capable of taking the received capsule out in finely cut state is used. At using time, the capsule is finely cut and oils and fats component is compulsorily mixed with the aqueous solution component to be emulsified, then the capsule component is dispersed to fine granular state by the capsule-destroying agent.
Introduction. The highest levels of childhood overweight and obesity in Latin America correspond to Argentina; this condition increases the risk of obesity, type 2 diabetes, cardiovascular and cerebrovascular diseases, and other conditions in adulthood. More than 25% of childhood and adolescent obesity are attributable to the consumption of sugar-sweetened beverages (SSBs). Our objective was to assess the disease and financial burden of SSB consumption among children and adolescents in Río Negro, the morbidity and mortality in adulthood, and the impact of reducing sugar consumption via the implementation of Law no. 27642 on the Promotion of Healthy Eating. Population and methods. We used a mathematical simulation model with a comparative risk assessment approach in the Río Negro population aged 0 to 17 years. The burden of obesity attributable to SSB consumption in the short and long term and direct medical costs were assessed. Results. The average consumption of SSBs was 348 mL/day; the prevalence of overweight and obesity was 16.6% and 11.6%, respectively. There were over 6600 cases of overweight in children and adolescents; while in adulthood, there were over 17 500 cases of overweight, 34 deaths attributable to SSBs, 3200 cases of diabetes, and over 4230 other health events. Direct medical costs were estimated at ARS 250 000 000 attributable to SSB consumption. Conclusion. The implementation of a comprehensive policy as established by Law no. 27642 on the Promotion of Healthy Eating in Río Negro would decrease 24% of overweight cases, morbidity, mortality, and associated medical costs.
This study aims to investigate whether a Late-Life Schizophrenia-Integrated Care Pathway (LLS-ICP) is superior to treatment as usual (TAU) in the treatment of psychotic symptoms of patients with schizophrenia or schizoaffective disorder. The investigators hypothesize that the LLS-ICP will be superior to TAU and result in 1.higher rates of response, 2. shorter times to response, 3. less side effects, 4. and better functional outcomes. The LLS-ICP study will be the first randomized controlled study to assess the efficacy of an ICP in patients with schizophrenia or schizoaffective disorder in this region. If successful, it will lead to the development of new and innovative approaches to health care delivery to patients with chronic schizophrenia or schizoaffective disorder not just within this institution but also at other sites in the community. The nature of ICPs as algorithmic and systematic in providing assessments and treatments render them ideal to be disseminated to medical practice outside of the institution of where they have been developed. These settings can include primary care clinics, supportive living environments, and long-term care homes where patients with chronic schizophrenia or schizoaffective disorder are being cared for.
The NUC under investigation is a regenerative medicine product comprised of the patient's own smooth muscle cells, procured from a fat biopsy. Tengion has developed appropriate culture conditions to reproducibly generate the necessary quantities of SMC in vitro from autologous adipose tissue biopsies. The NUC is produced at Tengion's Good Manufacturing Practices (GMP) qualified clinical production facility. In this process, smooth muscle cells (SMC) obtained from an adipose tissue biopsy are propagated ex-vivo for approximately 3 - 4 weeks. At the end of this process, the SMCs are seeded onto the surface of a biodegradable PGA/PLGA mesh scaffold to form the NUC. The NUC is shipped to the investigative site for surgical implantation. Over time, the NUC should facilitate the regeneration of urinary tract tissue.
Provided herein is a novel binding pocket within NEDD8 co-E3 proteins that binds NEDD8 E2 enzymes. Particularly at its M-Terminus. Methods are provided for screening for compounds that bind to the disclosed E2-binding pocket in NEDD8 co-E3 proteins. Compounds that bind to the E2-binding pocket and optionally inhibit the activity of NEDD8 co-E3 proteins and pharmaceutical compositions comprising the same are further provided. The NEDD8 co-E3 inhibitors find use, as agents preventing the NEDDylation of a target protein, in inhibiting cell growth and methods for treating cancers, inflammatory disorders, and pathogenic infections. The preferred inhibitors are peptides corresponding to a M-terminal fragment of Dncl, e.g. MTLASKLKRDD, MLKLRQLQKKKQ, and MIKLFSLKQQKK, which are substituted at the M-Terminus with an uncharged group (e.g. acyl).
Control group of eligible women patients between 45-60 years who do not receive the intervention at the West Palm Beach and Orlando Veterans Healthcare System. Usual care participants did not receive the educational secure messages.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: pharmaceutical compositions in the form of a mouth dissolving tablet are described. The composition contains an effective amount of a narcotic active material representing fentanyl, and arginine being a pharmaceutically acceptable amine. The molar ratio of arginine to said active material is at least approximately 5:1. In the preferential version of the invention, tablet disintegration time in vivo is 5 to 25 minutes. ^ EFFECT: invention provides enhanced fentanyl absorption in transbuccal administration of the tablets. ^ 7 cl, 2 tbl, 3 ex
The Armeo Spring system is an adjustable arm orthosis that has received FDA 510K clearance. It passively counterbalances the weight of the arm, thereby reducing the effort required to overcome gravity during the performance of upper-limb movements. The device provides subjects with augmented feedback via a virtual environment (i.e. computer games). The tasks to be performed in the virtual environment are designed to achieve functional movements, such as arm reaching movements.

The goal of the study is to assess the clinical outcomes of upper extremity training using the Armeo Spring system in a chronic post-stroke population with impaired upper extremity function. The Armeo Spring system is equipped with a grip sensor that subjects squeeze with their hand to interact with virtual objects during the games. In a first phase of the study, we attempted to replace the grip sensor that is part of the system with a sensorized glove, to facilitate a more natural movement of hand opening/closing. However, we experienced technical difficulties with the sensorized glove and decided to abandon this aim for the purpose of gathering data about the clinical outcomes of upper extremity training using the Armeo Spring system.
This is a single-arm, open-label, phase I study of combination therapy with SOM 230 LAR and standard treatment with gemcitabine. We will utilize a staggered, sequential dose-escalation design to define the maximum tolerated dose (MTD) of SOM 230 LAR when combined with standard doses of gemcitabine. Cycle will be defined as 28 days.

Treatment will be administered on an outpatient basis. Gemcitabine is administered by IV infusion. The dose should be based on the patient's actual baseline body weight; the dose will be recalculated if there is a weight change of \> 10% from baseline. The dose of gemcitabine will be given over 30 minutes, weekly every 3 weeks followed by 1 week rest period. SOM 230 LAR will be administered as an intramuscular dose determined by the dosing schema, every month.
The inclusion will be stratified into 2 groups according to the type of basal insulin being at baseline (ratio 1: 1): NPH human insulin / Long-acting basal insulin analogues. The type of insulin will not be changed by this protocol.
The invention discloses a kind of medical services platform construction methods based on portable medical pattern, the described method comprises the following steps：The first step, the medical service system design based on mobile intelligent terminal, a. give system business analysis and modeling；B. functional selection is carried out to doctor and nurse respectively；C. system design constraints condition is analyzed, and system architecture is introduced；D. the system structure model at doctor terminal and nurse end is introduced；E. cross-platform data exchange is realized using webservice technologies；F. it proposes a kind of method of the level-set segmentation based on threshold value under conditions of multithreading and processing is split to image；Second step, system is realized and test.The medical services platform construction method based on portable medical pattern of the present invention, using mobile intelligent terminal as platform, builds the portable medical pattern towards mobile Internet, and have devised and embodied the medical service system based on mobile intelligent terminal.
Insurance claim and underwriting assistance system and implementation method thereof are disclosed. The present system can extract multiple keyword strings from an electronic medical record and establish the grammatical structure of the whole electronic medical record. After that, the system can compare a medical vocabulary reference table (such as medical dictionary) and a disease classification reference table (such as ICD-10) to find out the closest medical vocabularies and the closest disease standard codes, and after that the system can determine whether the disease names corresponding to the disease standard code appears in the insurance terms of the insurance policy. If there is a match, then the system can assign a first identification mark (e.g. highlight label) to the extracted keyword strings shown in the electronic medical record, and after that the system can assign the second identification mark to an auxiliary interpretation reference table corresponding to the comparison result of insurance terms, and finally integrate the electronic medical record embedded with the first identification mark and the auxiliary interpretation reference table embedded with the second identification mark into an intelligent medical record. In this way, the intelligent medical record generated by the present system can not only improve the efficiency in underwriting operation or claim settlement operation, but also reduce the possibility of omission and misjudgments in the claim settlement operation.
Participants in this group will be between the ages of 7 and 18 years old and have no history of neurological disorder or brain injury. Amadeo will be used to train the non-dominant hand of participants in this group. The training will last approximately 1 hour per day for 14 successive days. Participants will be asked to first do active finger and passive finger moving, then receive haptic vibration, and finally play interactive games.
The participant with long bone defect or bone tumor of the extremity is referred to the Radiology Department to have a full CT-scan of both limbs to facilitate the later reconstruction. With the contralateral limb CT-scan data, the implant is designed with appropriate geometry and structures through online meetings with the scientists of CSIRO, Australia. Through this discussion, the supporting guides for the precise osteotomy will also be designed and would be 3D-printed later by 3 Dimensional Tech Vision Limited Company (Vietnam) with Poly Lactic Acid material. The 3D-printed metal parts will be manufactured using Titanium - 6 Aluminum - 4 Vanadium ELI (Extra Low Interstitial) material with Electron Beam Melting technology in CSIRO (Australia). Subsequently, the 3D-printed part will undergo mechanical tests using the Instron 5500R system (Australia) to validate its required mechanical properties. If this metal part cannot fulfill the mechanical requirements, the problematic geometry will be revised and re-designed. Another prototype will be 3D-printed with the same protocol and be tested until it qualified for the mechanical requirement. When the 3D-printed model passes the mechanical test, another 3D-printed metal part with a similar design will be manufactured before transferring to 3-Dimensional Tech Vision Limited Company (Vietnam) for post-processing, surface finishing, sterilising, packaging, labeling. Eventually, the implant will be sent to Cho Ray hospital. The amount of intraoperative blood loss and operative time will be recorded.
The present invention discloses a technology of an indomethacin adhesive plaster. An indomethacin adhesive plaster is a novel transdermal therapeutic system prepared from indomethacin used as main medicine, a transdermic accelerating agent, cosolvent, adhesive, etc. In the system, the indomethacin used as main medicine can penetrate through the skin to directly act on the affected region, and medicine can be released for a long time in substrate. The indomethacin adhesive plaster has the controlled release function, and after the indomethacin adhesive plaster is pasted on the part of the skin, no stimulation, or hypersensitivity, or exfoliation reaction occurs. The technology of an indomethacin adhesive plaster has obvious social benefits. The indomethacin adhesive plaster prepared according to the technology has the broad market, and therefore, the indomethacin adhesive plaster has obvious economic benefits.
High Aerobic Exercise Group: perform three exercise sessions per week consisting of about 45-60 minutes of aerobic exercise at a moderate-to-vigorous intensity. Again, participant can choose from different exercise equipment.
Although leucine zipper tumour suppressor 1 (LZTS1) has been considered a potential tumour suppressor, accumulating evidence suggests that LZTS1 is highly expressed in many cancer types. To unravel the exact role of LZTS1 in colorectal carcinogenesis, we performed the bioinformatic analysis of LZTS1, including expression differences, correlations between expression levels and survival, methylation status of LZTS1 promoter and related cellular pathways based on TCGA dataset, GEO databases and our own CRC patient cohort. Furthermore, we confirmed the oncogenic function of LZTS1 in human mammalian cells by employing a series of assays including tissue microarray, immunoblotting, cell proliferation and migration assay. We found that the expression of LZTS1 is higher in tumour samples compared to paired normal tissue in CRC cancer and its different clinical subtypes, which is, at least in part, due to the low methylation status of LZTS1 promoter in CRC tumour samples. Functional analysis identified the close relationship between high expression of LZTS1 and PI3K-AKT pathway and the epithelial-mesenchymal transition (EMT) process. Consistently, we found that the expression of LZTS1 positively correlated with the expression PIK3CD, N-cadherin in CRC tumour samples, while the expression of LZTS1 negatively correlated with the expression of E-cadherin and PTEN in CRC tumour samples. Experimental data further confirmed that overexpression of LZTS1 upregulated activity of AKT and promoted EMT process. Furthermore, depletion of LZTS1 repressed the proliferation and migration rate of CRC cells. Thus, this study indicates that LZTS1 plays an oncogenic role in colorectal carcinogenesis.
The present invention relates to a two-layered high moisturizing cosmetic composition containing a capsule, and a method for producing the same. More specifically, the present invention relates to a two-layered high moisturizing cosmetic composition containing a capsule, which includes 0.1 to 15.0 wt% of polyol, 0.1 to 0.5 wt% of an increasing agent, 0.1 to 10.0 wt% of microemulsion, and 1.0 to 20.0 wt% of a capsule with respect to a total weight of the cosmetic composition, and a method for producing the same. When the cosmetic composition according to the present invention is applied to skin, a high content of oil in a capsule is slowly emitted, so a skin moisturizing effect is maintained for a long time. Compared to general solubilizing-type low viscosity mist having rare continuous moisturizing maintaining strength, a skin moisturizing effect is remarkably excellent. Furthermore, since a capsule included in a cosmetic composition according to the present invention is large to be visually shown, a discriminated appearance can be exhibited. A formulation is formed in a two-layered structure, so visual interests may be provided to consumers through a way of shaking and mixing components in an upper layer part and a lower layer part.